FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112156978> ?p ?o ?g. }

• W2112156978 endingPage "1205" @default.
• W2112156978 startingPage "1200" @default.
• W2112156978 abstract "<h3>Abstract</h3> <b>Objectives:</b> To assess the efficacy and tolerability of aminosidine compared with sodium stibogluconate for treating visceral leishmaniasis. <b>Design:</b> Randomised, unblinded, controlled trial with 180 day follow up. <b>Setting:</b> Kala-Azar Research Centre, Brahmpura, Muzaffarpur, Bihar, India. <b>Subjects:</b> People of either sex aged 6-50 years with symptoms and signs suggestive of visceral leishmaniasis (fever, loss of appetite, enlarged spleen) with leishmania amastigotes detected in Giemsa stained aspirates of spleen or bone marrow. <b>Interventions:</b> Aminosidine at three daily doses (12, 16, and 20 mg/kg) for 21 days and sodium stibogluconate 20 mg/kg/day for 30 days. <b>Main outcome measures:</b> Laboratory measures of efficacy: parasite count, haemoglobin concentration, white cell count, platelet count, serum albumin concentration. Clinical measures of efficacy: spleen size, fever, body weight, and liver size. Measures of safety: liver and renal function tests, reports of adverse events. <b>Results:</b> Of the 120 patients enrolled (30 per treatment arm), 119 completed treatment and follow up. Cure at end of follow up was achieved in 23 (77%), 28 (93%), and 29 (97%) patients treated with 12, 16, and 20 mg aminosidine/kg/day respectively, and in 19 (63%) patients given sodium stibogluconate. At 16 and 20 mg/kg/day, aminosidine was significantly more active than sodium stibogluconate in both clinical and laboratory measures of efficacy. No significant clinical or laboratory toxicity occurred in any treatment group. <b>Conclusions:</b> A 21 day course of aminosidine 16 or 20 mg/kg/day should be considered as first line treatment for visceral leishmaniasis in Bihar. <h3>Key messages</h3> Bihar in north east India accounts for about half the annual worldwide cases of visceral leishmaniasis, and resistance to standard treatment with sodium stibogluconate has been increasing We compared the safety and efficacy of three doses of aminosidine with standard regimen of sodium stibogluconate for treating visceral leishmaniasis in Bihar Aminosidine given at 16 or 20 mg/kg/day for 21 days was significantly more effective in producing final cure than sodium stibogluconate 20 mg/kg/day for 30 days Aminosidine had a low incidence of adverse reactions, including ototoxicity and renal toxicity, and was well tolerated Intramuscular injection of aminosidine 16 mg/kg/day for 21 days should be considered as a new first line treatment for visceral leishmaniasis in Bihar" @default.
• W2112156978 created "2016-06-24" @default.
• W2112156978 creator A5011462633 @default.
• W2112156978 creator A5020201829 @default.
• W2112156978 creator A5022661236 @default.
• W2112156978 creator A5026005923 @default.
• W2112156978 creator A5032075904 @default.
• W2112156978 creator A5033745165 @default.
• W2112156978 creator A5054185332 @default.
• W2112156978 creator A5072672575 @default.
• W2112156978 creator A5088702000 @default.
• W2112156978 creator A5090058421 @default.
• W2112156978 date "1998-04-18" @default.
• W2112156978 modified "2023-10-16" @default.
• W2112156978 title "Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India Commentary: Some good news for treatment of visceral leishmaniasis in Bihar" @default.
• W2112156978 cites W1835042769 @default.
• W2112156978 cites W1964008976 @default.
• W2112156978 cites W1971420146 @default.
• W2112156978 cites W1983584866 @default.
• W2112156978 cites W1983770853 @default.
• W2112156978 cites W2005581369 @default.
• W2112156978 cites W2019179314 @default.
• W2112156978 cites W2037884319 @default.
• W2112156978 cites W2138942859 @default.
• W2112156978 cites W2142409861 @default.
• W2112156978 cites W2143743051 @default.
• W2112156978 cites W2148589496 @default.
• W2112156978 cites W2151324264 @default.
• W2112156978 cites W2155911139 @default.
• W2112156978 cites W2164004846 @default.
• W2112156978 cites W2180975734 @default.
• W2112156978 cites W2333833986 @default.
• W2112156978 cites W2394887674 @default.
• W2112156978 cites W2418553033 @default.
• W2112156978 cites W2422844201 @default.
• W2112156978 cites W39665744 @default.
• W2112156978 doi "https://doi.org/10.1136/bmj.316.7139.1200" @default.
• W2112156978 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/28521" @default.
• W2112156978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9583927" @default.
• W2112156978 hasPublicationYear "1998" @default.
• W2112156978 type Work @default.
• W2112156978 sameAs 2112156978 @default.
• W2112156978 citedByCount "158" @default.
• W2112156978 countsByYear W21121569782012 @default.
• W2112156978 countsByYear W21121569782013 @default.
• W2112156978 countsByYear W21121569782014 @default.
• W2112156978 countsByYear W21121569782015 @default.
• W2112156978 countsByYear W21121569782016 @default.
• W2112156978 countsByYear W21121569782017 @default.
• W2112156978 countsByYear W21121569782018 @default.
• W2112156978 countsByYear W21121569782019 @default.
• W2112156978 countsByYear W21121569782021 @default.
• W2112156978 countsByYear W21121569782022 @default.
• W2112156978 countsByYear W21121569782023 @default.
• W2112156978 crossrefType "journal-article" @default.
• W2112156978 hasAuthorship W2112156978A5011462633 @default.
• W2112156978 hasAuthorship W2112156978A5020201829 @default.
• W2112156978 hasAuthorship W2112156978A5022661236 @default.
• W2112156978 hasAuthorship W2112156978A5026005923 @default.
• W2112156978 hasAuthorship W2112156978A5032075904 @default.
• W2112156978 hasAuthorship W2112156978A5033745165 @default.
• W2112156978 hasAuthorship W2112156978A5054185332 @default.
• W2112156978 hasAuthorship W2112156978A5072672575 @default.
• W2112156978 hasAuthorship W2112156978A5088702000 @default.
• W2112156978 hasAuthorship W2112156978A5090058421 @default.
• W2112156978 hasBestOaLocation W21121569781 @default.
• W2112156978 hasConcept C126322002 @default.
• W2112156978 hasConcept C141071460 @default.
• W2112156978 hasConcept C197934379 @default.
• W2112156978 hasConcept C203014093 @default.
• W2112156978 hasConcept C2776114741 @default.
• W2112156978 hasConcept C2776555147 @default.
• W2112156978 hasConcept C2777787772 @default.
• W2112156978 hasConcept C2778375690 @default.
• W2112156978 hasConcept C2778689377 @default.
• W2112156978 hasConcept C2780122544 @default.
• W2112156978 hasConcept C501593827 @default.
• W2112156978 hasConcept C71924100 @default.
• W2112156978 hasConcept C86803240 @default.
• W2112156978 hasConcept C89423630 @default.
• W2112156978 hasConcept C90924648 @default.
• W2112156978 hasConceptScore W2112156978C126322002 @default.
• W2112156978 hasConceptScore W2112156978C141071460 @default.
• W2112156978 hasConceptScore W2112156978C197934379 @default.
• W2112156978 hasConceptScore W2112156978C203014093 @default.
• W2112156978 hasConceptScore W2112156978C2776114741 @default.
• W2112156978 hasConceptScore W2112156978C2776555147 @default.
• W2112156978 hasConceptScore W2112156978C2777787772 @default.
• W2112156978 hasConceptScore W2112156978C2778375690 @default.
• W2112156978 hasConceptScore W2112156978C2778689377 @default.
• W2112156978 hasConceptScore W2112156978C2780122544 @default.
• W2112156978 hasConceptScore W2112156978C501593827 @default.
• W2112156978 hasConceptScore W2112156978C71924100 @default.
• W2112156978 hasConceptScore W2112156978C86803240 @default.
• W2112156978 hasConceptScore W2112156978C89423630 @default.
• W2112156978 hasConceptScore W2112156978C90924648 @default.
• W2112156978 hasIssue "7139" @default.
• W2112156978 hasLocation W21121569781 @default.

• next